1. Cazzola, M. & Malcovati, L. Myelodysplastic syndromes-—coping with ineffective hematopoiesis. N. Engl. J. Med. 352, 536–538 (2005).
2. Haase, D. et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2,124 patients. Blood 110, 4385–4395 (2007).
3. Bianchi, E. & Rogge, L. Dissecting oncogenes and tyrosine kinases in AML cells. MedGenMed 5, 10 (2003).
4. Silverman, L. R. et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7 (Suppl. 1), 21–29 (1993).
5. Zagonel, V. et al. 5-Aza-2'-deoxycytidine (decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 7 (Suppl. 1), 30–35 (1993).